Paul Melancon, Atlanta.
International Journal of Drug Policy: �œThe globalization of ayahuasca: Harm reduction or benefit maximization?”
Alli Feduccia, PhD, senior clinical data scientist, Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA.
Mayo Clinic: �œMonoamine oxidase inhibitors (MAOIs).”
Multidisciplinary Association for Psychedelic Studies: �œAyahuasca.”
United States Drug Enforcement Administration: �œDrug Scheduling.”
David Olson, PhD, assistant professor, department of biochemistry and molecular medicine and department of chemistry, University of California, Davis.
Frontiers in Pharmacology: �œThe Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization.”
Jonathan Goldman, Essential Light Institute, Bend, OR.